Affy Debuts miRNA Offering as It Looks to Grow Expression Business in Competitive Market

An Affy spokesperson said the firm's interest in the market is an extension of its gene-expression profiling play, and said several "key advantages" over rival tools could enable it to profit in the market, which is poised to grow 25 percent through 2015.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories